Stock Evaluator: Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals, Inc. ACXP

$1.44 0.00 0.00%
August 3, 2026 12:15:16 PM EST November 10, 2021 Volume: 110,788
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Commentary & Analysis


Financial Summary

Share Statistics ACXP Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $6.2 $252.6 5%
Shares Out (Mil) 2.7 52.3 9%
Institutional Ownership 79.0% 92.1% 48%
Float (Mil) 4.2 40.2 10%
Beta -2.09 0.95 0%
Avg Daily Volume (000s) 74 455 32%
Price Change
(52-week)
(78.2%) 52.9% 7%
Growth ACXP Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (11.7%) (9.9%) 27%
EPS (5yr) 18.6% 16.0% 65
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 2.8% (15.6%) 66%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS ($0.435) ($1.970) ($2.130)
Month Ago EPS ($0.435) ($1.970) ($2.130)
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS ($0.555) ($2.390) ($2.200)
Year/Year Chg (29.6%) (62.9%) (54.8%)
Financials ACXP Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $38 na
Net Income (TTM) (Mil) ($8) ($43) 31%
EPS (TTM) ($3.889) ($1.600) 9%
Operating Cash Flow (TTM) (Mil) ($6) ($31) 23%
Net Cash Flow (TTM) (Mil) na $5 na
Long-Term Debt (Q1) (Mil) $0 $5 0%
Enterprise Value (Q1) (Mil) ($3) $180 3%
Valuation ACXP Industry
Median
Percentile
(All Stocks)
P/B 0.70 2.56 14%
P/E na 19.0 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios ACXP Industry
Median
Percentile
(All Stocks)
Gross Margin na 63.8% na
Net Margin na (67.3%) na
ROA (104.5%) (49.8%) 5%
ROE (160.8%) (55.5%) 6%
Liabilities to Assets 26.5% 30.3% 18%
F-Score 3 3 19%

Acurx Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors